Galectin Therapeutics presented new data from its NAVIGATE trial at EASL 2026 showing that belapectin 2 mg/kg demonstrated statistically significant reduction in new varices development at 18 months (p=0.04) and improvements in liver stiffness in patients with advanced MASH cirrhosis. The poster presentation on portal hypertension risk reduction ...

Galectin Therapeutics reported Q3 2025 financial results, highlighting promising biomarker data from the NAVIGATE trial for belapectin in treating MASH cirrhosis. The company submitted data to the FDA and is seeking guidance on next steps, with encouraging results showing potential disease progression reduction.

Galectin Therapeutics is hosting a virtual event to discuss its drug belapectin for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. The event will feature key opinion leaders and highlight results from the company's NAVIGATE Phase 3 clinical trial.

Galectin Therapeutics announced that the top-line results of the NAVIGATE trial in patients with MASH cirrhosis and portal hypertension will be presented at the 2025 MASH-TAG Conference. The company's executive leadership will also host one-on-one meetings during the JP Morgan Healthcare Conference to discuss the NAVIGATE topline results and the ...

Galectin Therapeutics reported financial results for Q2 2024, with a net loss of $12.4 million. The company's lead drug, belapectin, is in a Phase 2b/3 trial for the treatment of MASH-related liver cirrhosis, with interim data expected in December 2024.